Population Pharmacokinetics of Meropenem Across the Adult Lifespan.

ABSTRACT:

Background and objective

We conducted an opportunistic pharmacokinetic study to evaluate the population pharmacokinetics of meropenem, an antimicrobial commonly used to treat Gram-negative infections in adults of different ages, including older adults, and determined optimal dosing regimens.

Methods

A total of 99 patients were included. The population pharmacokinetic models used had two compartments: zero-order input and linear elimination. Covariates evaluated included renal function, body size, age, sex, vasopressor use, and frailty, using the Canadian Study of Health and Aging Clinical Frailty score (in patients aged ≥ 65 years). We simulated optimal dosing regimens by renal function and by age group to achieve therapeutic target attainment.

Results

Participants' a

SUBMITTER: Boutzoukas AE 

PROVIDER: S-EPMC12181987 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature